Med BioGene - Med BioGene Announces Publication of Data Demonstrating Independent Validation of GeneFx® Lung

Current News

June 1, 2015

MedBiogene Provides Update

May 21, 2015

Med BioGene Issues Revised Fact Sheet

May 21, 2015

Med BioGene Engages IR Company

April 9, 2015

Additional International Exposure for MBI’s commercialization Partner

March 26, 2015

Neil Campbell, the CEO of Helomics®, Message on Cancer Video

March 26, 2015

First 10 Industry Partners Announced

March 26, 2015

Helomics - 100,000 Genomes Project

March 3, 2015

Appointment Of New Director

February 16, 2015

MBI Closes Shares For Debt Transaction

February 3, 2015

Med BioGene Provide Shareholders Update

January 13, 2015

MBI Announces Shares For Debt Transaction

November 30, 2014

Financial Statement

October 02, 2014

Status Update Precision Therapeutics Inc. to Med Biogene Inc.

October 01, 2014

Closing of Private Placement

September 05, 2014

Directors Nominated By Dissident Shareholder Elected At Annual General Meeting

September 04, 2014

Med BioGene Announces Receipt of Proxies for Upcoming Annual and Special Meeting

August 29, 2014

Med BioGene Reports Financial Results for Q2 2014

August 21, 2014

Med BioGene Responds to Assertions Made by Dissident Shareholder

August 15, 2014

Med BioGene Provides Update and Announces Proposed Financing

August 06, 2014

Med BioGene Announces Director Nominations and Postponement of Annual and Special Meeting

May 30, 2014

Med BioGene Reports Financial Results for Q1 2014

April 30, 2014

Med BioGene Reports Financial Results for 2013

March 24, 2014

Med BioGene Announces Regulatory Approval of GeneFx® Lung

March 07, 2014

Med BioGene Announces Publication of Data Demonstrating Independent Validation of GeneFx® Lung

January 09, 2014

Med BioGene Announces Dismissal of Litigation With Signal Genetics LLC and Respira Health LLC

News Archives

2013 2012 2011 2010 2009 2008 2007 2006

Home

News

2015

Neil Campbell, the CEO of Helomics®, Message on Cancer Video

Neil Campbell, the CEO of Helomics® Corporation, the licensee responsible of the commercialization of GeneFx Lung®, Med BioGene's proprietary prognostic genomic based test procedure for early stage non-small cell lung cancers, NSCLC, talks about Helomics® approach to personalized medicine. The video was produced in the Helomics® CLIA approved laboratory at their headquarters in Pittsburgh.